Education
About Us
Working with TipRanks
Follow Us
Mesoblast (MESO)
NASDAQ:MESO
Earnings Data
Report Date
Sep 02, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
<0.01Last Year’s EPS
-0.43Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed strong commercial momentum following the successful Ryoncil launch (USD 49M H1 revenue, 93% gross margin), meaningful market access achievements (coverage for >280M lives, J-code, centers onboarded), robust cash and financing flexibility (USD 130M cash and new USD 125M facility), and compelling randomized data for Revascor and progress on rexlemestrocel-L. Offsetting these positives are sharp increases in R&D and SG&A as the company scales commercialization and advances clinical programs, continued operating losses and notable dependency on a single launched product while other programs mature. Overall, the call emphasized execution progress, regulatory engagement, and a clear path for near-term milestones, with manageable financial and execution risks.Company Guidance
Successful Ryoncil Launch and Revenue Contribution
Ryoncil launched April 2025 and drove the period: net product revenues of USD 49.0M in H1 FY26, representing ~95.5% of total revenues (USD 51.3M). Management reports quarter-on-quarter revenue growth since launch.
Very High Gross Margin
Reported gross margin of 93% for the period. Management noted gross profit excluding amortization of approximately USD 44.2M.
Strong Market Access and Commercial Momentum
49 treatment centers onboarded to date; Ryoncil listed on the formulary at 30 centers. Coverage established across payers representing over 280 million lives, Medicaid coverage in all states, and a specific J-code (J3402) effective Oct 1 to streamline billing. 13 hospitals use the Optum Frontier specialty pharmacy to reduce site financial burden.
Clear Market Penetration Targets and Uptake
Company is on track to achieve 20% pediatric market penetration by the end of year 1 post-launch and assumes a 40% peak share in its models for the pediatric population.
Robust Cash and Financing Position
USD 130M cash on hand as of Dec 31, 2025, plus a new USD 125M nondilutive credit facility (USD 75M drawn at closing; USD 50M available to draw through June 2026). Facility is lower cost, non-asset-cross-collateralized, and repayable without prepayment penalties.
Improved Net Loss YoY
Net loss of USD 40.2M in H1 FY26, improved from a USD 48.0M loss in the prior year period (approximate 16.3% improvement), with prior-year comparatives impacted by a one-time USD 23M inventory provision reversal.
Revascor (LVAD) Strong Randomized Data
LVAD II (159 patients, 2:1) and supportive LVAD I showed statistically significant reductions in major bleeding events and related hospitalizations through 6 and 12 months. Company reported ~fivefold reduction in major bleeding events/hospitalizations over 12 months versus control and evidence the treatment mitigates right-heart-failure-related mortality (control HR >7 for death if right-heart hospitalization occurred; treated group showed near abolition of early mortality risk).
Strategic Regulatory Pathway for Revascor
Based on randomized controlled data and orphan designation, Mesoblast is moving from seeking accelerated approval to filing for full BLA approval for the LVAD/right heart failure indication; BLA filing expected next quarter.
Progress on Second-Generation rexlemestrocel-L (Back Pain)
First Phase III (404 patients) completed with FDA feedback that a 12-month pain reduction endpoint is approvable. A confirmatory Phase III is enrolling 300 patients across ~40 U.S. sites with enrollment expected complete in March/April 2026; data readout and potential BLA filing expected in calendar 2027.
Operational Priorities and Manufacturing Focus
Management emphasized building manufacturing capacity/diversification, cost efficiencies, and commercial manufacturing readiness for both Ryoncil and rexlemestrocel-L to support commercialization and filings (CMC/potency activities underway).
FY26 Ryoncil Guidance
Company projects full-year FY26 Ryoncil net revenues of USD 110M–120M (fiscal year ending June 2026).
MESO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MESO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $16.91 | $16.92 | +0.06% |
Aug 28, 2025 | $15.95 | $13.83 | -13.29% |
May 28, 2025 | $10.97 | $10.95 | -0.18% |
Feb 26, 2025 | $15.72 | $15.54 | -1.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mesoblast (MESO) report earnings?
Mesoblast (MESO) is schdueled to report earning on Sep 02, 2026, TBA (Confirmed).
What is Mesoblast (MESO) earnings time?
Mesoblast (MESO) earnings time is at Sep 02, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MESO EPS forecast?
MESO EPS forecast for the fiscal quarter 2026 (Q4) is <0.01.